mTOR pathway as a target in tissue hypertrophy

Annual Review of Pharmacology and Toxicology

Volumn 47, Issue , 2007, Pages 443-467

  Lee, Chung Han ^a,b   Inoki, Ken ^a,b   Guan, Kun Liang ^a,b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

AKT; Cancer; Muscle; Rapamycin; TSC

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; PROTEIN TORC1; PROTEIN TORC2; PROTEIN TSC1; TUBERIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

CELL GROWTH; CELL SIZE; GROWTH REGULATION; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY HYPERTROPHY; MUSCLE HYPERTROPHY; NEPHROSIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTENOSIS; REVIEW;

ANTIBIOTICS, ANTINEOPLASTIC; CELL SIZE; HUMANS; HYPERTROPHY; MUSCLES; NEOPLASMS; PROTEIN KINASES; SIROLIMUS;

MAMMALIA; RAPTORES;

EID: 33847079961     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.47.120505.105359     Document Type: Review

References (106)

1. Inoki K, Ouyang H, Li Y, Guan KL. 2005. Signaling by target of rapamycin proteins in cell growth control. Microbiol. Mol. Biol. Rev. 69:79-100
2. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, et al. 1997. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805-8
3. Wienecke R, Konig A, DeClue JE. 1995. Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J. Biol. Chem. 270:16409-14
4. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, et al. 2002. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11:525-34
5. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, et al. 2003. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-akt signaling through downregulation of PDGFR. J. Clin. Invest. 112:1223-33
6. Nellist M, van Slegtenhorst MA, Goedbloed M, van den Ouweland AM, Halley DJ, van der Sluijs P. 1999. Characterization of the cytosolic tuberinhamartin complex. Tuberin is a cytosolic chaperone for hamartin. J. Biol. Chem. 274:35647-52
7. Chong-Kopera H, Inoki K, Li Y, Zhu T, Garcia-Gonzalo FR, et al. 2006. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J. Biol. Chem. 281:8313-16
8. Murthy V, Han S, Beauchamp RL, Smith N, Haddad LA, et al. 2004. Pam and its ortholog highwire interact with and may negatively regulate the TSC1, TSC2 complex. J. Biol. Chem. 279:1351-58
9. Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, et al. 2002. Tsc tumor suppressor proteins antagonize amino-acid-TOR signaling. Nat. Cell Biol. 4:699-704
10. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. 2003. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward rheb. Curr. Biol. 13:1259-68
11. Li Y, Inoki K, Guan KL. 2004. Biochemical and functional characterizations of small GTPase rheb and TSC2 GAP activity. Mol. Cell. Biol. 24:7965-75
12. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. 2003. Rheb is a direct target of the tuberous sclerosis tumor suppressor proteins. Nat. Cell Biol. 5:578-81
13. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, et al. 2003. Insulin activation of rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11:1457-66
14. Inoki K, Li Y, Xu T, Guan KL. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17:1829-34
15. Castro AF, Rebhun JF, Clark GJ, Quilliam LA. 2003. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278:32493-96
16. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. 2005. Rheb binds and regulates the mTOR kinase. Curr. Biol. 15:702-13
17. Long X, Ortiz-Vega S, Lin Y, Avruch J. 2005. Rheb binding to mTOR is regulated by amino acid sufficiency. J. Biol. Chem. 280(25):23433-36
18. Smith EM, Finn SG, Tee AR, Browne GJ, Proud CG. 2005. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J. Biol. Chem. 280:18717-27
19. Urano J, Comiso MJ, Guo L, Aspuria PJ, Deniskin R, et al. 2005. Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, rheb, in fission yeast. Mol. Microbiol. 58:1074-86
20. Li Y, Corradetti MN, Inoki K, Guan KL. 2004. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci. 29:32-38
21. Manning BD, Cantley LC. 2003. Rheb fills a GAP between TSC and TOR. Trends Biochem. Sci. 28:573-76
22. Tzatsos A, Kandror KV. 2006. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol. Cell. Biol. 26:63-76
23. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N. 1998. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the akt(PKB) signaling pathway. Genes Dev. 12:502-13
24. Inoki K, Li Y, Zhu T, Wu J, Guan KL. 2002. TSC2 is phosphorylated and inhibited by akt and suppresses mTOR signaling. Nat. Cell Biol. 4:648-57
25. Potter CJ, Pedraza LG, Xu T. 2002. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4:658-65
26. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10:151-62
27. Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, et al. 2006. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J. Cell Biol. 173:279-89
28. Dong J, Pan D. 2004. Tsc2 is not a critical target of akt during normal Drosophila development. Genes Dev. 18:2479-84
29. Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, et al. 2005. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 19:2199-11
30. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, et al. 2001. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15:2852-64
31. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, et al. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163-75
32. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, et al. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177-89
33. Schalm SS, Blenis J. 2002. Identification of a conserved motif required for mTOR signaling. Curr. Biol. 12:632-39
34. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, et al. 2003. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278:15461-64
35. Schalm SS, Fingar DC, Sabatini DM, Blenis J. 2003. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 13:797-806
36. Tee AR, Proud CG. 2002. Caspase cleavage of initiation factor 4E-binding protein 1 yields a dominant inhibitor of cap-dependent translation and reveals a novel regulatory motif. Mol. Cell Biol. 22:1674-83
37. Beugnet A, Wang X, Proud CG. 2003. Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1. J. Biol. Chem. 278:40717-22
38. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. 1994. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78:35-43
39. Peterson RT, Beal PA, Comb MJ, Schreiber SL. 2000. FKBP12-rapamycin- associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J. Biol. Chem. 275:7416-23
40. Mayeur GL, Fraser CS, Peiretti F, Block KL, Hershey JWB. 2003. Characterization of eIF3k: A newly discovered subunit of mammalian translation initiation factor eIF3. Eur. J. Biochem. 270:4133-39
41. Gingras AC, Raught B, Sonenberg N. 2001. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15:807-26
42. Holz MK, Ballif BA, Gygi SP, Blenis J. 2005. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123:569-80
43. McManus EJ, Collins BJ, Ashby PR, Prescott AR, Murray-Tait V, et al. 2004. The in vivo role of PtdIns(3, 4, 5)P3 binding to PDK1 PH domain defined by knockin mutation. EMBO J. 23:2071-82
44. Collins BJ, Deak M, Arthur JS, Armit LJ, Alessi DR. 2003. In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J. 22:4202-11
45. Raught B, Gingras AC, Gygi SP, Imataka H, Morino S, et al. 2000. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J. 19:434-44
46. Harris TE, Chi A, Shabanowitz J, Hunt DF, Rhoads RE, Lawrence JC. 2006. mTOR-dependent stimulation of the association of eIF4G and eIF3 by insulin. EMBO J. 25:1659-68
47. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, et al. 2004. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200-5
48. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, et al. 2004. The TSC 1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213-23
49. Shah OJ, Wang Z, Hunter T. 2004. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14:1650-56
50. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, et al. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22(2):159-68
51. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, et al. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6:1122-28
52. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, et al. 2002. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10:457-68
53. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, et al. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14:1296-302
54. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-201
55. Hresko RC, Mueckler M. 2005. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280:40406-16
56. Ali SM, Sabatini DM. 2005. Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. J. Biol. Chem. 280:19445-48
57. Kamada Y, Fujioka Y, Suzuki NN, Inagaki F, Wullschleger S, et al. 2005. Tor2 directly phosphorylates the AGC kinase Ypk2 to regulate actin polarization. Mol. Cell. Biol. 25:7239-48
58. Lee C, Kim JS, Waldman T. 2004. PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells. Canc. Res. 64:6906-14
59. Kwon CH, Zhu X, Zhang J, Baker SJ. 2003. mTor is required for hypertrophy of pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. USA 100:12923-28
60. Gao X, Pan D. 2001. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 15:1383-92
61. Radimerski T, Montagne J, Hemmings-Mieszczak M, Thomas G. 2002. Lethality of drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes Dev. 16:2627-32
62. Yang Q, Inoki K, Kim E, Guan KL. 2006. TSC1/TSC2 and rheb have different effects on TORC1 and TORC2 activity. Proc. Natl. Acad. Sci. USA 103(18):6811-16
63. Zhang H, Stallock JP, Ng JC, Reinhard C, Neufeld TP. 2000. Regulation of cellular growth by the drosophila target of rapamycin dTOR. Genes Dev. 14:2712-24
64. Oldham S, Montagne J, Radimerski T, Thomas G, Hafen E. 2000. Genetic and biochemical characterization of dTOR, the drosophila homolog of the target of rapamycin. Genes Dev. 14:2689-94
65. Lee-Fruman KK, Kuo CJ, Lippincott J, Terada N, Blenis J. 1999. Characterization of S6K2, a novel kinase homologous to S6K1. Oncogene 18:5108-14
66. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, et al. 2004. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24:3112-24
67. Sulic S, Panic L, Barkic M, Mercep M, Uzelac M, Volarevic S. 2005. Inactivation of S6 ribosomal protein gene in T lymphocytes activates a p53-dependent checkpoint response. Genes Dev. 19:3070-82
68. Richardson CJ, Broenstrup M, Fingar DC, Julich K, Ballif BA, et al. 2004. SKAR is a specific target of S6 kinase 1 in cell growth control. Curr. Biol. 14:1540-49
69. Musaro A, Rosenthal N. 1999. Maturation of the myogenic program is induced by postmitotic expression of insulin-like growth factor I. Mol. Cell. Biol. 19:3115-24
70. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. 2005. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J. Clin. Invest. 115:451-58
71. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, et al. 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3:1009-13
72. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, et al. 2001. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3:1014-19
73. Pallafacchina G, Calabria E, Serrano AL, Kalhovde JM, Schiaffino S. 2002. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc. Natl. Acad. Sci. USA 99:9213-18
74. Atherton PJ, Babraj J, Smith K, Singh J, Rennie MJ, Wackerhage H. 2005. Selective activation of AMPK-PGC-1alpha or PKB-TSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation. FASEB J. 19:786-88
75. Ohanna M, Sobering AK, Lapointe T, Lorenzo L, Fraud C, et al. 2005. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat. Cell Biol. 7:286-94
76. Guillet C, Prod'homme M, Balage M, Gachon P, Giraudet C, et al. 2004. Impaired anabolic response of muscle protein synthesis is associated with S6K1 dysregulation in elderly humans. FASEB J. 18:1586-87
77. Shioi T, McMullen JR, Tarnavski O, Converse K, Sherwood MC, et al. 2003. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107:1664-70
78. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, et al. 2004. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109:3050-55
79. Wang L, Gout I, Proud CG. 2001. Cross-talk between the ERK and p70 S6 kinase (S6K) signaling pathways. MEK-dependent activation of S6K2 in cardiomyocytes. J. Biol. Chem. 276:32670-77
80. Wang L, Proud CG. 2002. Ras/Erk signaling is essential for activation of protein synthesis by gq protein-coupled receptor agonists in adult cardiomyocytes. Circ. Res. 91:821-29
81. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. 2004. Tumor-promoting phorbol esters and activated ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. USA 101:13489-94
82. Rolfe M, McLeod LE, Pratt PF, Proud CG. 2005. Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). Biochem. J. 388:973-84
83. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. 2005. Phosphorylation and functional inactivation of TSC2 by erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121:179-93
84. Giasson E, Meloche S. 1995. Role of p70 S6 protein kinase in angiotensin II-induced protein synthesis in vascular smooth muscle cells. J. Biol. Chem. 270:5225-31
85. Hafizi S, Wang X, Chester AH, Yacoub MH, Proud CG. 2004. ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 287:H1232-38
86. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, et al. 2003. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362:1093-99
87. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, et al. 2003. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349:1315-23
88. Silberberg J. 2003. What's major about adverse cardiac events? Lancet 362:1860
89. Weisz G, Leon MB, Holmes DRJ, Kereiakes DJ, Clark MR, et al. 2006. Two-year outcomes after sirolimus-eluting stent implantation: results from the sirolimus-eluting stent in de novo native coronary lesions (SIRIUS) trial. J. Am. Coll. Cardiol. 47:1350-55
90. Ebina M, Takahashi T, Chiba T, Motomiya M. 1993. Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D morphometric study. Am. Rev. Respir. Dis. 148:720-26
91. Fujitani Y, Trifilieff A. 2003. In vivo and in vitro effects of SAR 943, a rapamycin analogue, on airway inflammation and remodeling. Am. J. Respir. Crit. Care Med. 167:193-98
92. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, et al. 2002. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem. 277:30958-67
93. Goncharova EA, Goncharov DA, Spaits M, Noonan DJ, Talovskaya E, et al. 2006. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: role for tumor suppressor TSC2. Am. J. Respir. Cell Mol. Biol. 34:561-72
94. Guertin DA, Sabatini DM. 2005. An expanding role for mTOR in cancer. Trends Mol. Med. 11:353-61
95. Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, et al. 2000. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 408:994-97
96. Hashimoto N, Kido Y, Uchida T, Asahara S, Shigeyama Y, et al. 2006. Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat. Genet. 38:589-93
97. Chen JK, Chen J, Neilson EG, Harris RC. 2005. Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J. Am. Soc. Nephrol. 16:1384-91
98. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A. 2006. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem. Biophys. Res. Commun. 340:296-301
99. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, et al. 2006. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J. Am. Soc. Nephrol. 17:1395-404
100. Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, et al. 2005. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int. 68:552-61
101. Scott RC, Schuldiner O, Neufeld TP. 2004. Role and regulation of starvation-induced autophagy in the drosophila fat body. Dev. Cell 7:167-78
102. Rusten TE, Lindmo K, Juhasz G, Sass M, Seglen PO, et al. 2004. Programmed autophagy in the drosophila fat body is induced by ecdysone through regulation of the PI3K pathway. Dev. Cell 7:179-92
103. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, et al. 2004. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of huntington disease. Nat. Genet. 36:585-95
104. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, et al. 2006. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15:433-42
105. Ravikumar B, Berger Z, Vacher C, O'Kane CJ, Rubinsztein DC. 2006. Rapamycin pretreatment protects against apoptosis. Hum. Mol. Genet. 15:1209-16
106. Rosner M, Freilinger A, Hengstschlager M. 2006. Akt regulates nuclear/cytoplasmic localization of tuberin. Oncogene. In press